Xenon Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $2.33 billion
- Book Value:
- Revenue TTM:
- $9.43 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Xenon Pharmaceuticals Inc had its IPO on 2014-11-05 under the ticker symbol XENE.
The company operates in the Healthcare sector and Biotechnology industry. Xenon Pharmaceuticals Inc has a staff strength of 203 employees.
Shares of Xenon Pharmaceuticals Inc opened at $36.33 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $35.31 - $36.35, and closed at $35.61.
This is a -1.55% slip from the previous day's closing price.
A total volume of 322,809 shares were traded at the close of the day’s session.
In the last one week, shares of Xenon Pharmaceuticals Inc have increased by +6.14%.
Xenon Pharmaceuticals Inc's Key Ratios
Xenon Pharmaceuticals Inc has a market cap of $2.33 billion, indicating a price to book ratio of 3.2172 and a price to sales ratio of 181.4446.
In the last 12-months Xenon Pharmaceuticals Inc’s revenue was $9.43 million with a gross profit of $-96333000 and an EBITDA of $-127519000. The EBITDA ratio measures Xenon Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Xenon Pharmaceuticals Inc’s operating margin was -1368.91% while its return on assets stood at -12.17% with a return of equity of -19.72%.
In Q4, Xenon Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Xenon Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.06. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Xenon Pharmaceuticals Inc’s profitability.
Xenon Pharmaceuticals Inc stock is trading at a EV to sales ratio of 136.051 and a EV to EBITDA ratio of -16.4147. Its price to sales ratio in the trailing 12-months stood at 181.4446.
Xenon Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $754.15 million
- Total Liabilities
- $32.65 million
- Operating Cash Flow
- Capital Expenditure
- $1.75 million
- Dividend Payout Ratio
Xenon Pharmaceuticals Inc ended 2023 with $754.15 million in total assets and $0 in total liabilities. Its intangible assets were valued at $754.15 million while shareholder equity stood at $721.50 million.
Xenon Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $32.65 million in other current liabilities, 1065136000.00 in common stock, $-482747000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $57.24 million and cash and short-term investments were $592.09 million. The company’s total short-term debt was $10,435,000 while long-term debt stood at $0.
Xenon Pharmaceuticals Inc’s total current assets stands at $593.07 million while long-term investments were $128.68 million and short-term investments were $534.85 million. Its net receivables were $986000.00 compared to accounts payable of $22.21 million and inventory worth $0.
In 2023, Xenon Pharmaceuticals Inc's operating cash flow was $-14335000.00 while its capital expenditure stood at $1.75 million.
Comparatively, Xenon Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Xenon Pharmaceuticals Inc stock is currently trading at $35.61 per share. It touched a 52-week high of $41.39 and a 52-week low of $41.39. Analysts tracking the stock have a 12-month average target price of $50.85.
Its 50-day moving average was $36.96 and 200-day moving average was $36.1 The short ratio stood at 8.68 indicating a short percent outstanding of 0%.
Around 169.1% of the company’s stock are held by insiders while 9896.1% are held by institutions.
Frequently Asked Questions About Xenon Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company’s product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.